Searching for ultra-low emission engines particularly for automotive applications is still ongoing. Even though LTC combustion mode results a prominent advantages in terms of reducing both NO and PM and also lowering the consumption of fuel, it mainly faces with the challenge of excess emissions of HC and CO. This study aimed to optimize the operating control factors for low emissions in PCCI-DI engine under LTC mode. Parameters include injection timing, EGR level, dieseline ratio and engine load. Computation of analyzing the grey relation with hybrid of Taguchi was applied. In designing of experiments and conducting tests Taguchi's L matrix was applied. Air-blast of methanol intake port supply and dieseline application instead of diesel was implemented aiming emission reductions. Optimum combinations were found using GRA and ANOVA. Following the optimization work; advanced injection timing of 25 before TDC, 25% EGR, dieseline 90:10 in % and load 75 % (ABCD) was found optimal combination level for the proposed aim of emission reductions. Key findings of the results following the experiment conducted using this optimal combination includes; reduction of 68.02% NO and 62.37% in smoke comparing with the base-line conventional diesel combustion mode. Rankings and ANOVA indicated another findings that injection timing being most influential with a contribution of 69.35% followed by load, dieseline ratio and EGR level respectively. This study confirmed dieseline direct injection with methanol port injection is capable of reducing emissions and better NO with HC and CO trade-offs in PCCI-DI engines.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194597 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2022.e09679 | DOI Listing |
Phytomedicine
December 2024
Institute of Integrated Traditional Chinese and Western Medicine, Chinese Evidence-based Medicine Center and Cochrane China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China; West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. Electronic address:
Background: Multidrug resistance organisms (MDROs) pose a major threat in intensive care units (ICUs). Although in vitro studies suggested that Tanreqing (TRQ) was effective against MDROs, evidence about TRQ injection usage and its real-world effectiveness is lacking.
Purpose: This study aimed to investigate treatment pattern and real-world effectiveness of TRQ against MDRO infections among ICU patients being treated with antibiotics.
Tijdschr Psychiatr
January 2025
Background: The SPACe 2: STAR trial is a multicenter trial in children with an autism spectrum disorder, divided over nine centers in the Netherlands. However, it is challenging to include enough participants due to various factors, including the varying status of the disorder and willingness of parents and children.
Aim: To identify and overcome the bottlenecks for practitioners during the trial to prevent major delays.
Sci Rep
January 2025
School of Biological Sciences, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, 30332-0535, GA, USA.
Clin Infect Dis
January 2025
Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Background: Tenofovir-containing antiretroviral therapy (ART) improves survival in HBV-coinfected people with HIV (PWH). We investigated the incidence of HDV infection and its clinical impact in HBV-coinfected PWH in the era of tenofovir-containing ART.
Methods: Between 2011 and 2022, HBV-coinfected PWH were included and followed until December 2023.
F S Sci
December 2024
The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, NY, 10021, USA. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!